Bortezomib-based therapy for newly diagnosed mantle-cell lymphoma. - Test2 - elhamkhani - TriplyDB

Bortezomib-based therapy for newly diagnosed mantle-cell lymphoma.

Bortezomib-based therapy for newly diagnosed mantle-cell lymphoma.

http://www.wikidata.org/entity/Q33420889

about

Hard-Wired Bias: How Even Double-Blind, Randomized Controlled Trials Can Be Skewed From the Start Bortezomib for the treatment of mantle cell lymphoma: an update The role of targeted treatment in mantle cell lymphoma: is transplant dead or alive?Cost-effectiveness analysis of bortezomib in combination with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone (VR-CAP) in patients with previously untreated mantle cell lymphoma Ibrutinib in mantle cell lymphoma patients: glass half full? Evidence and opinion Allogeneic Hematopoietic Cell Transplantation as Curative Therapy for Patients with Non-Hodgkin Lymphoma: Increasingly Successful Application to Older Patients Mantle cell lymphoma in the era of precision medicine-diagnosis, biomarkers and therapeutic agents Outcomes of both abbreviated hyper-CVAD induction followed by autologous hematopoietic cell transplantation and conventional chemotherapy for mantle cell lymphoma: a 10-year single-centre experience with literature review A phase II study of bortezomib added to rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone in patients with previously untreated indolent non-Hodgkin's lymphoma.Lenalidomide plus Rituximab as Initial Treatment for Mantle-Cell Lymphoma.Bortezomib in the treatment of refractory thrombotic thrombocytopenic purpura.A phase I trial of bortezomib in combination with everolimus for treatment of relapsed/refractory non-Hodgkin lymphoma.Paclitaxel synergizes with exposure time adjusted CD22-targeting immunotoxins against B-cell malignancies.Synergistic interactions between PLK1 and HDAC inhibitors in non-Hodgkin's lymphoma cells occur in vitro and in vivo and proceed through multiple mechanisms Association between quality of response and outcomes in patients with newly diagnosed mantle cell lymphoma receiving VR-CAP versus R-CHOP in the phase 3 LYM-3002 study The novel β2-selective proteasome inhibitor LU-102 decreases phosphorylation of I kappa B and induces highly synergistic cytotoxicity in combination with ibrutinib in multiple myeloma cells.A phase II study of bortezomib in patients with relapsed or refractory aggressive adult T-cell leukemia/lymphoma.Frontline rituximab, cyclophosphamide, doxorubicin, and prednisone with bortezomib (VR-CAP) or vincristine (R-CHOP) for non-GCB DLBCL.Bortezomib in mantle cell lymphoma: comparative therapeutic outcomes Phase II trial of R-CHOP plus bortezomib induction therapy followed by bortezomib maintenance for newly diagnosed mantle cell lymphoma: SWOG S0601.Inhibition of IRE1α-driven pro-survival pathways is a promising therapeutic application in acute myeloid leukemia.Rationale and efficacy of proteasome inhibitor combined with arsenic trioxide in the treatment of acute promyelocytic leukemia.Phospholipid scramblase 1 as a critical node at the crossroad between autophagy and apoptosis in mantle cell lymphoma.Exome Sequencing Identifies Potentially Druggable Mutations in Nasopharyngeal Carcinoma.Association between bortezomib dose intensity and overall survival in mantle cell lymphoma patients on frontline VR-CAP in the phase 3 LYM-3002 study.Mantle Cell Lymphoma: First-line Therapy in Patients Not Eligible for Stem Cell Transplantation.Mantle cell lymphoma: 2015 update on diagnosis, risk-stratification, and clinical management.Bortezomib: A Review in Mantle Cell Lymphoma in Previously Untreated Patients Unsuitable for Stem-Cell Transplantation.Post-autologous transplant maintenance therapies in lymphoid malignancies: are we there yet?Bortezomib in the treatment of mantle cell lymphoma.Treatment options for mantle cell lymphoma.Will new drugs change the standard of care for patients with mantle cell lymphoma?Long-Term Results of High-Dose Therapy and Autologous Stem Cell Transplantation for Mantle Cell Lymphoma: Effectiveness of Maintenance Rituximab.Novel targeted therapeutics for mantle cell lymphoma--what's on the horizon?Risk of chemotherapy-induced neutropenic complications when treating patients with non-Hodgkin lymphoma.Kinesin-5 Blocker Monastrol Protects Against Bortezomib-Induced Peripheral Neurotoxicity.TG2 and NF-κB Signaling Coordinates the Survival of Mantle Cell Lymphoma Cells via IL6-Mediated Autophagy Efficacy of the GemOx-R regimen leads to the identification of Oxaliplatin as a highly effective drug against Mantle Cell Lymphoma.Which Patients With Mantle Cell Lymphoma Do Not Need Aggressive Therapy.Strategic role of the ubiquitin-dependent segregase p97 (VCP or Cdc48) in DNA replication.

P2860

Q24289425-819DC364-B1BC-48F0-8678-1D044AFC2CDA Q26738940-58980481-8DD8-4799-9E51-2A7C1794B494 Q26772907-A19A149E-66C6-4889-9F65-496E368228CC Q26779612-81926F01-EE1F-45E8-A03F-FA947CAE9C0F Q26783430-41D31C47-B8E2-4904-8594-83BD5A56F7CA Q28066710-83C2DC89-9452-4F5C-89A7-85E5566BFAFD Q28075606-EEBB2270-8AAD-4492-8C5D-0B17D15AF668 Q28087748-A5C418B5-147F-4DBD-AA4F-3FE5BCD06E24 Q33424956-F7A6AE8E-FF1D-47CC-B15A-D99BBAAA0464 Q33427312-77B074E0-1F28-452C-B45E-14259A32AFCD Q33430998-1EE11FE6-AB7D-48E1-9BB5-76425C898CA0 Q33443555-63A149DE-2E60-4832-BDAD-6204655B7E28 Q33761496-2B6C181C-D968-499E-9515-4804B1BBDA76 Q33761796-3D71F309-5331-4420-B027-77A8970EBCB5 Q33816002-F05E9A5C-C444-42AC-9724-DB8DEA806ED8 Q35889653-4AC7EA58-BE1A-4550-B05E-4470639CD2AA Q36092890-153A013F-7DF3-490F-98F5-2A75505D5530 Q36192439-47818EAF-FE2C-4159-9951-F42215F71641 Q36278006-DA98FA2F-1627-44BE-857E-60A3110EE2DB Q36456078-E9562403-3734-4FBD-BC7C-363D6773A7A2 Q37109858-A4F39852-F8E5-44A4-8BA9-9DB6B565F0B0 Q37396013-ACFFF9BE-0327-4E55-82C5-4A286BF853A0 Q37520396-652FF5A4-51C1-439F-9CE9-6320C3FB8C6B Q37678950-0D1170E8-2218-4975-9031-61E641A76753 Q38376021-451C1DA2-68F7-4BD4-82F7-DDE0683C93C3 Q38480491-563B016B-6A9C-459E-9B32-35F8F8ED6402 Q38535489-FFED0020-2BAC-4C0F-8118-20EFD165C9A4 Q38538693-9C7D73E9-7D35-4E19-B347-C6B6871C8FEF Q38568358-56741727-7105-4DF0-A98B-3BBC2297D051 Q38582650-99D27C34-8C9E-4C27-9203-48B6D06BD9B9 Q38584922-A52675C4-F8E6-413E-BAEC-0AF7046F42BF Q38658549-A66C60F8-80A0-4C2C-921B-26C9D7084B2F Q38667361-01B11D6D-199D-4BE0-B5B9-5A84075668E3 Q38675161-85DC3DD7-CAD5-482D-88D2-7E4E6164139F Q38711166-34D16D24-CCD0-4C30-8A17-1321A6450433 Q38726608-278EFB4E-4B9E-4CD8-8F39-A4F0F491C689 Q38734433-D14FACB1-CB67-49A3-90D2-4E62C7EE6775 Q38768797-03043237-F07A-4350-A2D0-0965BCA7BF8C Q38805552-D2889CE5-7E64-426B-B4AA-64F46729952E Q38810286-AA816881-77A0-4407-9EDD-6AC0006CD987

P2860

Bortezomib-based therapy for newly diagnosed mantle-cell lymphoma.

http://www.wikidata.org/entity/Q33420889

description

2015 nî lūn-bûn

@nan

2015 թուականի Մարտին հրատարակուած գիտական յօդուած

@hyw

2015 թվականի մարտին հրատարակված գիտական հոդված

@hy

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

name

Bortezomib-based therapy for newly diagnosed mantle-cell lymphoma.

@ast

Bortezomib-based therapy for newly diagnosed mantle-cell lymphoma.

@en

type

label

Bortezomib-based therapy for newly diagnosed mantle-cell lymphoma.

@ast

Bortezomib-based therapy for newly diagnosed mantle-cell lymphoma.

@en

prefLabel

Bortezomib-based therapy for newly diagnosed mantle-cell lymphoma.

@ast

Bortezomib-based therapy for newly diagnosed mantle-cell lymphoma.

@en

P1433

Q33420889-08D584E6-923E-4970-9BD8-5EE139FE0F05

P1476

Q33420889-3289D618-54BA-4026-AB48-68AC6A48F5F8

P2093

Q33420889-0124619F-C727-47A4-85CA-2834611C5038

Q33420889-09BF88F2-0F70-492A-9D2C-D6DEBDC56324

Q33420889-25757CEE-C25F-4C1D-86F6-7E3028FE12A2

Q33420889-27456AB4-E8C5-43A7-B0F0-F50EB1496231

Q33420889-45EDDE3D-EB22-4682-8B15-18C4DE0CBE72

Q33420889-4E3B7693-7B02-4EB7-8B17-9AABF0D930ED

Q33420889-522E39BB-04B1-47D0-97CD-0505E5A89543

Q33420889-55784712-F8D6-452F-AC58-EAD4A651211E

Q33420889-78EAB8BC-7700-413D-88CC-8788A081400A

Q33420889-95987EB8-8EB8-4D05-BA1D-44BB232F06D9

P304

Q33420889-E0306555-EEDE-42A8-8A7B-E49E28B3E108

P31

Q33420889-8568B51D-2DE7-45D5-B73A-76B5671321B7

P356

Q33420889-B1DF30A4-8650-41B2-B0D1-BD3B9DFD99F2

P407

Q33420889-9508CF37-CFE1-47BA-910F-3C893E0E540E

P433

Q33420889-2DAC7D9D-2861-4382-A801-CE59C00E97DC

P478

Q33420889-65C835F2-C45B-40DD-81C6-5BC57E22C86F

P50

Q33420889-ABC545B0-67ED-470B-8044-746369629AC4

Q33420889-BD7B3BF7-B77C-456D-B058-BA617A450BFE

P577

Q33420889-25C56C65-B15A-40FD-8CB7-AAE4D3107033

P698

Q33420889-C287A947-52FC-476C-AF38-1B85367BD66C

P356

P1433

The New England Journal of Medicine

P1476

Bortezomib-based therapy for newly diagnosed mantle-cell lymphoma.

@en

P2093

Brendan Rooney

http://www.w3.org/2001/XMLSchema#string

Franco Cavalli

http://www.w3.org/2001/XMLSchema#string

Halyna Pylypenko

http://www.w3.org/2001/XMLSchema#string

Helgi van de Velde

http://www.w3.org/2001/XMLSchema#string

Huiqiang Huang

http://www.w3.org/2001/XMLSchema#string

Jie Jin

http://www.w3.org/2001/XMLSchema#string

Jiri Mayer

http://www.w3.org/2001/XMLSchema#string

Johannes Drach

http://www.w3.org/2001/XMLSchema#string

Julia Alexeeva

http://www.w3.org/2001/XMLSchema#string

Juliana Pereira

http://www.w3.org/2001/XMLSchema#string

P304

944-953

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1056/NEJMOA1412096

http://www.w3.org/2001/XMLSchema#string

P407

P433

10

http://www.w3.org/2001/XMLSchema#string

P478

372

http://www.w3.org/2001/XMLSchema#string

P50

Evgenii A Osmanov

P577

2015-03-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

25738670

http://www.w3.org/2001/XMLSchema#string